Xenon Pharmaceuticals Announces Proposed Public Offering

Core Viewpoint - Xenon Pharmaceuticals Inc. has initiated a public offering of $500 million in common shares, with an additional option for underwriters to purchase up to $75 million more, subject to market conditions [1][2]. Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [6]. - The company is headquartered in Vancouver, British Columbia, and Boston, Massachusetts [7]. Product Pipeline - Xenon's lead molecule, azetukalner, is a KV7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [7]. - The company is also developing an early-stage portfolio of potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for pain treatment [7].